Real-time Stock quotes, portfolio, LIVE TV and more.
|
Jun 29, 2012, 10.41 AM IST
Alembic and Breckenridge announce paragraph IV ANDA litigation with Pfizer on desvenlafaxine
Breckenridge Pharmaceutical Inc USA and Alembic Pharmaceutical were named codefendants in a paragraph IV lawsuit filed by Pfizer Inc. concerning their ANDA desvenlafaxine succinate extended-release tablets 50mg and 100mg. a generic version of Pristiq by Pfizer Inc.
Breckenridge and Alembic filed their paragraph IV ANDA on the first-possible submission date and expects to share 180-day exclusively with other ANDA first filers. Alembic Pharma Ltd. is the sponsor and manufacturer of the ANDA, which will be marketed exclusively by Breckenridge.
Source : BSE
Read all announcements in Alembic Pharma
Related News Set email alert for |
Action in Alembic Pharmaceuticals
News Videos
|